This study will test the clinical effectiveness and safety of two orally administered doses of apremilast compared to placebo in Japanese patients with moderate-to-severe plaque-type psoriasis.
Apremilast (CC-10004) is a new oral agent that is under clinical development for the treatment of inflammatory autoimmune disorders such as psoriasis, psoriatic arthritis, ankylosing spondylitis, rheumatoid arthritis, and Behçet disease.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01988103?cond=%22Arthritis%22&lup_s=10/31/2013&lup_d=30
